Skip to main content

Boyer David W.'s Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Feb 8, 2023

Accession no.
0001209191-23-007909
Filed
Feb 8, 2023
Trade date
Feb 6-8, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $2.59M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Boyer David W.CIK 0001909817Officer (Chief Corp. Affairs Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 6, 2023Common StockSSaleDisposed−240$105.61F2−$25,346.44,127Direct
Feb 7, 2023Common StockSSaleDisposed−12,801$102.41F5−$1,310,950.4115,624Direct
Feb 7, 2023Common StockSSaleDisposed−11,497$102.42F7−$1,177,522.744,127Direct
Feb 8, 2023Common StockSSaleDisposed−700$104.11F9−$72,8774,755Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.67 to $107.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F5

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F7

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.93 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

Referenced by the price of 1 transaction in Table I.

F9

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)